<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04384692</url>
  </required_header>
  <id_info>
    <org_study_id>RG1006507</org_study_id>
    <secondary_id>NCI-2020-01626</secondary_id>
    <secondary_id>RG1006507</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <nct_id>NCT04384692</nct_id>
  </id_info>
  <brief_title>Ruxolitinib for the Treatment of Graft Versus Host Disease Following Stem Cell Transplant in Patients With Primary and Secondary Myelofibrosis</brief_title>
  <official_title>Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well administering ruxolitinib before, during, and after
      allogeneic hematopoietic stem cell transplantation works in preventing graft versus host
      disease and improving transplant outcomes in patients with primary and secondary
      myelofibrosis. Donor hematopoietic stem cell transplantation (HSCT) is currently the only
      treatment with proven curative potential for myelofibrosis, however, myelofibrosis patients
      have a high risk for developing graft versus host disease post-transplant. Graft versus host
      disease is a condition where the transplanted cells from a donor can attack the body's normal
      cells. Ruxolitinib, a janus-associated kinase (JAK) inhibitor, is known to decrease
      inflammatory signals, which may reduce spleen size and decrease symptoms such as night sweats
      and weight loss. Administering ruxolitinib before, during, and after transplant may decrease
      the incidence and severity of graft versus host disease, increase survival, and improve
      quality of life in patients with primary and secondary myelofibrosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OUTLINE:

      PART 1: Patients receive ruxolitinib intravenously (IV) starting 8 weeks prior to
      hematopoietic stem cell transplantation (HSCT) and continuing until approximately 14 days
      prior to conditioning regimen, then tapered per the treating clinician until day -4 in the
      absence of disease progression or unacceptable toxicity.

      PART 2: Patients are assigned to either a high (myeloablative) or reduced intensity
      conditioning regimen per the clinical provider together with the Clinical Coordinators Office
      (CCO):

      MYELOABLATIVE CONDITIONING: Patients receive cyclophosphamide IV on days -7 and -6 and
      busulfan IV on days -5 to -2. Patients with umbilical cord blood (UCB) as their transplant
      source also receive fludarabine IV on days -8 to -6. Treatment continues in the absence of
      disease progression or unacceptable toxicity.

      REDUCED INTENSITY CONDITIONING: Patients receive fludarabine IV on days -6 to -2 and
      melphalan IV on days -3 and -2. Patients with UCB as their transplant source also undergo
      total body irradiation (TBI) on day -1. Treatment continues in the absence of disease
      progression or unacceptable toxicity.

      TRANSPLANT: After completion of conditioning regimen, patients undergo HSCT on day 0.

      GVHD PROPHYLAXIS: Patients receive ruxolitinib until approximately 7 months post-transplant
      and then tapered over 2 months until 9 months post HSCT. Patients also receive tacrolimus IV
      continuously (inpatients) or every 12 hours (outpatients) beginning day -1 (day -3 for
      patients with UCB as their donor source), then orally (PO) twice daily (BID) once therapeutic
      levels are reached, with a taper beginning on day 56 for patients with related donors, and
      day 100 for patients with unrelated donors over 4 months in the absence of GVHD. The duration
      of tacrolimus for patients with GVHD is determined by the attending physician. Patients with
      related and unrelated donors also receive methotrexate IV on days 1, 3, 6, and 11. Patients
      with UCB as their transplant source also receive mycophenolate mofetil IV or PO every 8 hours
      beginning on days 0-30, then tapered until day 40 in the absence of GVHD. All treatment
      continues in the absence of disease progression or unacceptable toxicity.

      Patients are followed up at 6 months, 1 year, and 2-5 years after completion of HSCT.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of grade II-IV graft versus host disease (GVHD) in myelofibrosis patients</measure>
    <time_frame>Up to day 100</time_frame>
    <description>The probability of grade II-IV acute GVHD observed in this study will be compared to a fixed benchmark, this fixed benchmark derived from the results of a previous study (FH Protocol 9033).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of grade III-IV GVHD</measure>
    <time_frame>Up to day 100</time_frame>
    <description>Estimated as simple proportions and informally compared to the results from FH Protocol 9033.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of chronic GVHD</measure>
    <time_frame>Up 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival rate (OS)</measure>
    <time_frame>At 1 and 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of primary and secondary graft failure</measure>
    <time_frame>6 months</time_frame>
    <description>Estimated as simple proportions and informally compared to the results from FH Protocol 9033.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to neutrophil (ANC &gt; 500) engraftment</measure>
    <time_frame>Day 100</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to platelet (&gt; 20,000) engraftment</measure>
    <time_frame>Day 100</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of relapse</measure>
    <time_frame>At 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-relapse mortality (NRM)</measure>
    <time_frame>Day 100 and 1 year</time_frame>
    <description>Estimated as simple proportions and informally compared to the results from FH Protocol 9033.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Primary Myelofibrosis</condition>
  <condition>Secondary Myelofibrosis</condition>
  <arm_group>
    <arm_group_label>Treatment (ruxolitinib, conditioning, HSCT, GVHD prophylaxis)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See detailed description.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>Undergo HSCT</description>
    <arm_group_label>Treatment (ruxolitinib, conditioning, HSCT, GVHD prophylaxis)</arm_group_label>
    <other_name>Allogeneic Hematopoietic Cell Transplantation</other_name>
    <other_name>Allogeneic Stem Cell Transplantation</other_name>
    <other_name>HSC</other_name>
    <other_name>HSCT</other_name>
    <other_name>Stem Cell Transplantation, Allogeneic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (ruxolitinib, conditioning, HSCT, GVHD prophylaxis)</arm_group_label>
    <other_name>1, 4-Bis[methanesulfonoxy]butane</other_name>
    <other_name>BUS</other_name>
    <other_name>Bussulfam</other_name>
    <other_name>Busulfanum</other_name>
    <other_name>Busulfex</other_name>
    <other_name>Busulphan</other_name>
    <other_name>CB 2041</other_name>
    <other_name>CB-2041</other_name>
    <other_name>Glyzophrol</other_name>
    <other_name>GT 41</other_name>
    <other_name>GT-41</other_name>
    <other_name>Joacamine</other_name>
    <other_name>Methanesulfonic Acid Tetramethylene Ester</other_name>
    <other_name>Methanesulfonic acid, tetramethylene ester</other_name>
    <other_name>Mielucin</other_name>
    <other_name>Misulban</other_name>
    <other_name>Misulfan</other_name>
    <other_name>Mitosan</other_name>
    <other_name>Myeleukon</other_name>
    <other_name>Myeloleukon</other_name>
    <other_name>Myelosan</other_name>
    <other_name>Mylecytan</other_name>
    <other_name>Myleran</other_name>
    <other_name>Sulfabutin</other_name>
    <other_name>Tetramethylene Bis(methanesulfonate)</other_name>
    <other_name>Tetramethylene bis[methanesulfonate]</other_name>
    <other_name>WR-19508</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (ruxolitinib, conditioning, HSCT, GVHD prophylaxis)</arm_group_label>
    <other_name>(-)-Cyclophosphamide</other_name>
    <other_name>2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate</other_name>
    <other_name>Carloxan</other_name>
    <other_name>Ciclofosfamida</other_name>
    <other_name>Ciclofosfamide</other_name>
    <other_name>Cicloxal</other_name>
    <other_name>Clafen</other_name>
    <other_name>Claphene</other_name>
    <other_name>CP monohydrate</other_name>
    <other_name>CTX</other_name>
    <other_name>CYCLO-cell</other_name>
    <other_name>Cycloblastin</other_name>
    <other_name>Cycloblastine</other_name>
    <other_name>Cyclophospham</other_name>
    <other_name>Cyclophosphamid monohydrate</other_name>
    <other_name>Cyclophosphamide Monohydrate</other_name>
    <other_name>Cyclophosphamidum</other_name>
    <other_name>Cyclophosphan</other_name>
    <other_name>Cyclophosphane</other_name>
    <other_name>Cyclophosphanum</other_name>
    <other_name>Cyclostin</other_name>
    <other_name>Cyclostine</other_name>
    <other_name>Cytophosphan</other_name>
    <other_name>Cytophosphane</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Fosfaseron</other_name>
    <other_name>Genoxal</other_name>
    <other_name>Genuxal</other_name>
    <other_name>Ledoxina</other_name>
    <other_name>Mitoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Revimmune</other_name>
    <other_name>Syklofosfamid</other_name>
    <other_name>WR- 138719</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (ruxolitinib, conditioning, HSCT, GVHD prophylaxis)</arm_group_label>
    <other_name>Fluradosa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (ruxolitinib, conditioning, HSCT, GVHD prophylaxis)</arm_group_label>
    <other_name>Alanine Nitrogen Mustard</other_name>
    <other_name>CB-3025</other_name>
    <other_name>L-PAM</other_name>
    <other_name>L-Phenylalanine Mustard</other_name>
    <other_name>L-Sarcolysin</other_name>
    <other_name>L-Sarcolysin Phenylalanine mustard</other_name>
    <other_name>L-Sarcolysine</other_name>
    <other_name>Melphalanum</other_name>
    <other_name>Phenylalanine Mustard</other_name>
    <other_name>Phenylalanine Nitrogen Mustard</other_name>
    <other_name>Sarcoclorin</other_name>
    <other_name>Sarkolysin</other_name>
    <other_name>WR-19813</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (ruxolitinib, conditioning, HSCT, GVHD prophylaxis)</arm_group_label>
    <other_name>Abitrexate</other_name>
    <other_name>Alpha-Methopterin</other_name>
    <other_name>Amethopterin</other_name>
    <other_name>Brimexate</other_name>
    <other_name>CL 14377</other_name>
    <other_name>CL-14377</other_name>
    <other_name>Emtexate</other_name>
    <other_name>Emthexat</other_name>
    <other_name>Emthexate</other_name>
    <other_name>Farmitrexat</other_name>
    <other_name>Fauldexato</other_name>
    <other_name>Folex</other_name>
    <other_name>Folex PFS</other_name>
    <other_name>Lantarel</other_name>
    <other_name>Ledertrexate</other_name>
    <other_name>Lumexon</other_name>
    <other_name>Maxtrex</other_name>
    <other_name>Medsatrexate</other_name>
    <other_name>Metex</other_name>
    <other_name>Methoblastin</other_name>
    <other_name>Methotrexate LPF</other_name>
    <other_name>Methotrexate Methylaminopterin</other_name>
    <other_name>Methotrexatum</other_name>
    <other_name>Metotrexato</other_name>
    <other_name>Metrotex</other_name>
    <other_name>Mexate</other_name>
    <other_name>Mexate-AQ</other_name>
    <other_name>MTX</other_name>
    <other_name>Novatrex</other_name>
    <other_name>Rheumatrex</other_name>
    <other_name>Texate</other_name>
    <other_name>Tremetex</other_name>
    <other_name>Trexeron</other_name>
    <other_name>Trixilem</other_name>
    <other_name>WR-19039</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>Given IV or PO</description>
    <arm_group_label>Treatment (ruxolitinib, conditioning, HSCT, GVHD prophylaxis)</arm_group_label>
    <other_name>CellCept</other_name>
    <other_name>MMF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ruxolitinib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (ruxolitinib, conditioning, HSCT, GVHD prophylaxis)</arm_group_label>
    <other_name>INCB-18424</other_name>
    <other_name>INCB18424</other_name>
    <other_name>Jakafi</other_name>
    <other_name>Oral JAK Inhibitor INCB18424</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Given IV and PO</description>
    <arm_group_label>Treatment (ruxolitinib, conditioning, HSCT, GVHD prophylaxis)</arm_group_label>
    <other_name>FK 506</other_name>
    <other_name>Fujimycin</other_name>
    <other_name>Hecoria</other_name>
    <other_name>Prograf</other_name>
    <other_name>Protopic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total-Body Irradiation</intervention_name>
    <description>Undergo TBI</description>
    <arm_group_label>Treatment (ruxolitinib, conditioning, HSCT, GVHD prophylaxis)</arm_group_label>
    <other_name>TBI</other_name>
    <other_name>Total Body Irradiation</other_name>
    <other_name>Whole Body Irradiation</other_name>
    <other_name>Whole-Body Irradiation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  JAK INHIBITOR ADMINISTRATION INCLUSION: (PART I)

          -  Disease criteria:

               -  Diagnosis of primary myelofibrosis (PMF) as defined by the 2016 World Health
                  Organization classification system or diagnosis of secondary myelofibrosis (MF)
                  as defined by the International Working Group (IWG) for Myeloproliferative
                  Neoplasms Research and Treatment criteria

               -  Patients meeting the criteria for intermediate-1, intermediate-2 or high-risk
                  disease by Dynamic International Prognostic Scoring System (DIPSS) or DIPSS plus

          -  Ability to understand and the willingness to sign a written informed consent document

          -  Patient must be a potential hematopoietic stem cell transplant candidate as assessed
             by the consenting physician

          -  Patient must be willing to start ruxolitinib within a 6-month time period

          -  ALLOGENEIC STEM CELL TRANSPLANT INCLUSION: (PART II)

          -  Meeting criteria for part 1, as above, at time of initiation of ruxolitinib, including
             the ability to understand and willingness to sign a written informed consent. Patients
             arriving to our institution for transplant and not enrolled in part 1 may still be
             enrolled in part 2 if part 1 criteria are met. These patients will have part 1
             endpoints transcribed from medical records

          -  Received ruxolitinib for at least 8 weeks immediately prior to conditioning and be
             willing to continue until 9 months post-transplant as tolerated

          -  Performance status score: Karnofsky &gt;= 70

          -  Calculated creatinine clearance using the Cockcroft-Gault formula or 24 hour (hr)
             urine creatinine clearance must be &gt; 60 ml/min

          -  Total serum bilirubin must be &lt; 3 mg/dL unless the elevation is thought to be due to
             Gilbert's disease or hemolysis

          -  Transaminases must be &lt; 3 x the upper limit of normal

          -  Patients with clinical or laboratory evidence of liver disease will be evaluated for
             the cause of liver disease, its clinical severity in terms of liver function, and the
             degree of portal hypertension. Patients with fulminant liver failure, cirrhosis with
             evidence of portal hypertension or bridging fibrosis, alcoholic hepatitis, hepatic
             encephalopathy, or correctable hepatic synthetic dysfunction evidenced by prolongation
             of the prothrombin time, ascites related to portal hypertension, bacterial or fungal
             abscess, biliary obstruction, chronic viral hepatitis with total serum bilirubin &gt;
             3mg/dL, and symptomatic biliary disease will be excluded

          -  Diffusion capacity of lung for carbon monoxide (DLCO) corrected &gt; 60% normal. May be
             not be on supplemental oxygen

          -  Left ventricular ejection fraction &gt; 40% OR shortening fraction &gt; 26%

          -  Comorbidity index &lt; 5 at the time of pre-transplant evaluation

        Exclusion Criteria:

          -  JAK INHIBITOR ADMINISTRATION EXCLUSION: (PART I)

          -  Contraindication to receiving ruxolitinib including:

               -  Patients who have known hypersensitivity to JAK inhibitors

               -  Clinical or laboratory evidence of significant renal or hepatic impairment
                  including cirrhosis

               -  Active uncontrolled infection

               -  Known human immunodeficiency virus (HIV) positivity

               -  Women who are pregnant or trying to conceive

               -  Caution should be used in patients with platelets &lt; 100 though adjustments in
                  dose can be made to accommodate anyone with platelets &gt; 50

          -  History of prior allogeneic transplant

          -  Leukemic transformation (&gt; 20% blasts)

          -  ALLOGENEIC STEM CELL TRANSPLANT EXCLUSION: (PART II)

          -  Uncontrolled viral or bacterial infection at the time of transplant data review and
             consent conference

          -  Active or recent (prior 6 month) invasive fungal infection without infectious disease
             (ID) consult and approval

          -  History of HIV infection

          -  Pregnant or breastfeeding

          -  Patients without a human leukocyte antigen (HLA)-identical sibling donor, 10 of 10
             HLA-matched or 9 of 10 allele mismatched unrelated donor, or umbilical cord blood
             units that meet transplant criteria

          -  Patients with a spleen &gt; 22 cm (&gt;16 cm for cord blood patients) who have NOT received
             a surgical splenectomy consultation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rachel B. Salit</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rachel B. Salit</last_name>
    <phone>206.667.1317</phone>
    <email>rsalit@fredhutch.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Rachel B. Salit</last_name>
      <phone>206-667-1317</phone>
      <email>rsalit@fredhutch.org</email>
    </contact>
    <investigator>
      <last_name>Rachel B. Salit</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 8, 2020</study_first_submitted>
  <study_first_submitted_qc>May 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2020</study_first_posted>
  <last_update_submitted>July 1, 2020</last_update_submitted>
  <last_update_submitted_qc>July 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Primary Myelofibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Mechlorethamine</mesh_term>
    <mesh_term>Nitrogen Mustard Compounds</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

